Gene News and Research

Latest Gene News and Research

Many parents share BRCA1/A2 test results with their children

A new study has found that when parents get tested for breast cancer genes, many of them share their results with their children, even with those who are very young. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study also revealed that most parents think that their children are not distressed when they learn about the test results.

9 Jan 2012

miRagen, Silence partner to assess delivery potential of novel miRNA-based therapeutics

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, announces that it has signed an agreement with miRagen Therapeutics, Inc., to assess the delivery potential of Silence's proprietary DBTC delivery system with miRagen's novel microRNA-based therapeutics.

9 Jan 2012

MPIIB, QIAGEN partner to develop latent TB diagnostic test

QIAGEN N.V. and the Max Planck Institute for Infection Biology (MPIIB), Department of Immunology have announced a new collaboration to develop a molecular diagnostic test to assess the risk of an individual with latent tuberculosis (TB) developing active TB disease during their lifetime.

From QIAGEN Manchester Limited 9 Jan 2012

Scientists identify two genes involved in major symptoms of MeCP2 duplication disorder

The anxiety and behavioral issues associated with excess MeCP2 protein result from overexpression of two genes (Crh [corticotropin-releasing hormone] and Oprm 1 [mu-opioid receptor MOR 1]), which may point the way to treating these problems in patients with too much of the protein, said Baylor of Medicine scientists in a report that appears online in the journal Nature Genetics.

8 Jan 2012

AICAR therapy may combat heat stroke

We've all seen the story in the news before. Whether it's the death of a physically fit high school athlete at football training camp in August, or of an elderly woman gardening in the middle of the day in July, heat stroke is a serious, life-threatening condition for which there is no treatment beyond submersion in ice water or the application of ice packs to cool the body to a normal temperature.

8 Jan 2012

AccuGenomics to participate in OneMedForum at Sir Francis Drake hotel

AccuGenomics announced today that it will be attending the upcoming OneMedForum at the Sir Francis Drake hotel in San Francisco on January 9-12, coinciding with the JP Morgan Global Healthcare Conference.

7 Jan 2012

Study shows high consistency of malignancy-risk gene signature on both breast cancer and NSCLC

A malignancy-risk gene signature developed for breast cancer has been found to have predictive and prognostic value for patients with early stage non-small cell lung cancer. The advancement was made by researchers at Moffitt Cancer Center in Tampa, Fla., who published their study results in a recent issue of the Journal of the National Cancer Institute.

7 Jan 2012

ACLJ urges U.S. Supreme Court to declare flawed health care law unconstitutional

On behalf of nearly 120 members of Congress and more than 100,000 Americans, the American Center for Law and Justice (ACLJ) today urged the U.S. Supreme Court to conclude that a key provision of ObamaCare - the individual mandate - cannot be severed from the health care law and urged the high court to declare the entire law unconstitutional.

7 Jan 2012

Cardium resolves continued listing deficiencies with NYSE Amex

Cardium Therapeutics today reported that it had received notice from NYSE Regulation that the Company is now considered to have regained compliance with the listing requirements of the NYSE Amex LLC.

7 Jan 2012

Studies identify genes and small molecules against protein conformational diseases

Two related studies from Northwestern University offer new strategies for tackling the challenges of preventing and treating diseases of protein folding, such as Alzheimer's, Parkinson's and Huntington's diseases, amyotrophic lateral sclerosis (ALS), cancer, cystic fibrosis and type 2 diabetes.

7 Jan 2012

Alnylam files CTA with the U.K. MHRA to initiate ALN-TTR02 Phase I trial in ATTR

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.

7 Jan 2012

GSN completes $20M financing round

Gene Security Network Inc. (GSN) today announced the completion of a $20 million financing round, as well as the change of the company's name to Natera, Inc. The financing round was led by Lightspeed Venture Partners, which is joined in the current round by Claremont Creek Ventures and Sequoia Capital.

7 Jan 2012

Scripps professor receives pair of notable grants to study kinesin

Sathyanaryanan Puthanveettil, an assistant professor on the Florida campus of The Scripps Research Institute, has been awarded a pair of notable grants to study a critical component of long-term memory formation.

6 Jan 2012

QIAGEN introduces QIAensemble Decapper to facilitate handling of liquid samples

QIAGEN N.V. announced today the launch of the QIAensemble Decapper automation system that will facilitate the handling of liquid-based cytology and various other types of liquid samples that are processed by clinical laboratories around the world.

From QIAGEN Manchester Limited 6 Jan 2012

Isis announces results from ISIS-TTRRx Phase 1 study on TTR amyloidosis

Isis Pharmaceuticals, Inc. announced today results from a Phase 1 study with ISIS-TTRRx. The results demonstrated that treatment with ISIS-TTRRx produced dose-dependent statistically significant reductions of greater than 80 percent in transthyretin (TTR) protein.

6 Jan 2012

Researchers identify potential target for schistosomiasis vaccine

In the complicated life cycle of ancient flatworms that cause schistosomiasis, Case Western Reserve University researchers have identified a gene activator crucial to development of the parasites within humans - a potential target for a vaccine.

6 Jan 2012

Baxter commences BAX 855 Phase I trial in hemophilia A

Baxter International Inc. today announced the dosing of the first patients in a Phase I clinical trial of its lead investigational candidate, BAX 855, a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein.

From Baxter International Inc. 5 Jan 2012

RGS9-2 gene plays a role in regulating body weight

Abraham Kovoor was studying a brain protein, called RGS9 2, that he had previously related to the involuntary, random and repetitive body movements that are side effects of drugs used to treat Parkinson's disease and schizophrenia.

5 Jan 2012

Positive preliminary results from Alnylam's Phase I ALN-PCS trial on severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the achievement of positive preliminary results from its ongoing clinical trial of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia.

5 Jan 2012

Arrowhead receives FDA IND approval for Adipotide obesity drug

Arrowhead Research Corporation, a nanomedicine company with development programs in oncology and obesity, today announced that the Investigational New Drug Application (IND) for its first obesity drug candidate, Adipotide, was accepted by the U.S. Food and Drug Administration allowing the initiation of a clinical trial to test the safety of the compound.

5 Jan 2012

Gene News and Research

Latest Gene News and Research

Many parents share BRCA1/A2 test results with their children

miRagen, Silence partner to assess delivery potential of novel miRNA-based therapeutics

MPIIB, QIAGEN partner to develop latent TB diagnostic test

Scientists identify two genes involved in major symptoms of MeCP2 duplication disorder

AICAR therapy may combat heat stroke

AccuGenomics to participate in OneMedForum at Sir Francis Drake hotel

Study shows high consistency of malignancy-risk gene signature on both breast cancer and NSCLC

ACLJ urges U.S. Supreme Court to declare flawed health care law unconstitutional

Cardium resolves continued listing deficiencies with NYSE Amex

Studies identify genes and small molecules against protein conformational diseases

Alnylam files CTA with the U.K. MHRA to initiate ALN-TTR02 Phase I trial in ATTR

GSN completes $20M financing round

Scripps professor receives pair of notable grants to study kinesin

QIAGEN introduces QIAensemble Decapper to facilitate handling of liquid samples

Isis announces results from ISIS-TTRRx Phase 1 study on TTR amyloidosis

Researchers identify potential target for schistosomiasis vaccine

Baxter commences BAX 855 Phase I trial in hemophilia A

RGS9-2 gene plays a role in regulating body weight

Positive preliminary results from Alnylam's Phase I ALN-PCS trial on severe hypercholesterolemia

Arrowhead receives FDA IND approval for Adipotide obesity drug

eBook: Using iPSCs models for human disease research and drug discovery eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research